Overview

Singulair Use in Non-Allergic Rhinitis Eosinophil Syndrome (NARES)

Status:
Unknown status
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to determine if patients with NARES treated with montelukast (Singulair) will have improved nasal symptom scores and reduced nasal eosinophils.
Phase:
Phase 4
Details
Lead Sponsor:
Bernstein, Jonathan A., M.D.
Collaborator:
Merck Sharp & Dohme Corp.
Treatments:
Montelukast